Skip to content
HowShorted

Moleculin Biotech, Inc. short interest in 2022

In 2022, Moleculin Biotech, Inc.'s disclosed short interest ran from 1.86% of shares outstanding on 14 Jan 2022 to 0.41% on 30 Dec 2022, a change of -1.45 percentage points. The year's high was 1.86% on 14 Jan 2022 and its low 0.18% on 31 Oct 2022, averaging 0.77% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 4.41 days on 15 Mar 2022. Full history: Moleculin Biotech, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2025

Aggregate net short position time series for Moleculin Biotech, Inc. in 2022

2022 in figures

Start of year
1.86% (14 Jan 2022)
End of year
0.41% (30 Dec 2022)
Change
-1.45 pp
High
1.86% (14 Jan 2022)
Low
0.18% (31 Oct 2022)
Average
0.77%
Highest days to cover
4.41 (15 Mar 2022)
SEC filings marked
8

Every report in 2022

Moleculin Biotech, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20221.86%3.14
31 Jan 20221.72%2.68
15 Feb 20221.55%4.05
28 Feb 20221.69%3.85
15 Mar 20221.53%4.41
31 Mar 20221.46%3.8410-K filed, results (8-K)
14 Apr 20221.46%3.92
29 Apr 20221.05%2.62
13 May 20220.66%2.3010-Q filed, results (8-K)
31 May 20220.87%4.30
15 Jun 20220.53%3.67
30 Jun 20220.33%2.11
15 Jul 20220.41%3.59
29 Jul 20220.19%1.00
15 Aug 20220.35%1.3810-Q filed, results (8-K)
31 Aug 20220.55%1.12
15 Sep 20220.33%1.00
30 Sep 20220.21%1.00
14 Oct 20220.20%1.20
31 Oct 20220.18%1.00
15 Nov 20220.24%1.0210-Q filed, results (8-K)
30 Nov 20220.31%1.00
15 Dec 20220.28%1.00
30 Dec 20220.41%1.03

See also: Moleculin Biotech, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.